Question 1

Where is the Fresenius Medical Care AG & Co. KGaA stock traded?

Accepted Answer

The Fresenius Medical Care AG & Co. KGaA stock trades under the ticker FME.XETRA on the XETRA exchange. ISIN: DE0005785802.

Question 2

What does Fresenius Medical Care AG & Co. KGaA do?

Accepted Answer

Fresenius Medical Care AG & Co. KGaA is a company characterized by the following investment thesis:

Question 3

What are the key metrics for FME.XETRA?

Accepted Answer

Key metrics for FME.XETRA include valuation (P/E 12.2, P/S 0.6, P/B 0.8), profitability (profit margin 4.83%, ROE 8.52%), and growth (revenue –, earnings –). Market capitalization is 10.87B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has Fresenius Medical Care AG & Co. KGaA's stock price performed?

Accepted Answer

Fresenius Medical Care AG & Co. KGaA's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is FME.XETRA valued?

Accepted Answer

FME.XETRA has the following valuation metrics: P/E Ratio: 12.2, P/S Ratio: 0.6, P/B Ratio: 0.8. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does FME.XETRA pay dividends?

Accepted Answer

Yes, FME.XETRA pays dividends with a dividend yield of 3.7%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in FME.XETRA?

Accepted Answer

Key risks for FME.XETRA include: Fresenius Medical Care holds a leading global position in dialysis products and renal care services. The company operates within a competitive landscape shaped by large dialysis service chains and medtech firms offering dialysis machines, consumables, and home dialysis solutions. Several structural risks merit attention. U.S. reimbursement rates and government payor policies exert substantial influence on financial performance. Regulatory frameworks vary significantly across markets, creating compliance complexity. Operational and supply-chain pressures persist alongside workforce challenges. The company's financial leverage amplifies sensitivity to macroeconomic shifts and interest-rate movements, creating cyclical vulnerability during periods of tightening monetary conditions.High dependence on U.S. reimbursement policies creates meaningful revenue risk if Medicare and Medicaid payment rates decline or coverage narrows.Regulatory and compliance obligations span multiple jurisdictions—medical device regulation, clinic licensing, quality standards, and anti-fraud requirements—each capable of raising operational costs or constraining how the business can function.Operational risks stem from supply-chain disruptions, shortages of dialysis consumables or devices, and workforce constraints that could diminish capacity or increase costs.Elevated debt levels create financial risk, particularly through interest-rate sensitivity that could constrain the company's flexibility for future investments or acquisitions.Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of Fresenius Medical Care AG & Co. KGaA?

Accepted Answer

Fresenius Medical Care AG & Co. KGaA competes with several listed peers in its sector. Fresenius Medical Care (FME.XETRA) operates as the world's largest dialysis services and products provider. Its competitive environment includes large publicly listed clinic operators and medtech companies supplying dialysis machines, disposables, and home-dialysis systems. The company faces material risks from reimbursement and regulatory pressure across major markets, competition from established clinic operators and cost-conscious device makers, supply-chain and commodity cost swings, and clinical and staffing challenges that can pressure utilization and margins.DaVita Inc. (DVA.NYSE)Baxter International Inc. (BAX.NYSE)Outset Medical, Inc. (OM.NASDAQ)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does Fresenius Medical Care AG & Co. KGaA report earnings?

Accepted Answer

Fresenius Medical Care AG & Co. KGaA's next earnings report date is November 3, 2026.

Period	P/E Ratio	P/S Ratio	P/B Ratio	P/CF Ratio
Current	11.2	0.5	0.8	3.7
1Y ago	19.6	0.7	1.0	4.7
3Y ago	17.2	0.6	0.9	5.0
5Y ago	17.8	1.0	1.5	7.2

Fresenius Medical Care AG & Co. KGaA P/E & Valuation

Valuation Metrics

Historical valuation trends

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more